$0.04
(Market cap
$1 Mln
Revenue (TTM)
$-14 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-13 Mln
-
ROE
-1.9 %
-
ROCE
-- %
-
Industry P/E
44.42
-
EV/EBITDA
-0.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-6
-
Face value
--
-
Shares outstanding
2,626,030
10 Years Aggregate
CFO
$-146.10 Mln
EBITDA
$-166.06 Mln
Net Profit
$-183.20 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biocept (BIOC)
| -99.6 | 55.1 | -95.2 | -99.6 | -92.1 | -80.6 | -- |
|
BSE Sensex*
| -10.9 | -4.9 | -8.9 | -7.6 | 6.9 | 8.3 | 11.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Biocept (BIOC)
| -99.6 | -85.4 | -18.5 | 55.2 | -66.7 | -95.8 | -10.5 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Biocept (BIOC)
|
0.1 | 1.1 | -14.4 | -46.2 | 209.8 | -1009.6 | -- | 0.4 |
| 8.1 | 5,380.1 | 6,552.2 | -551.4 | -4.3 | -9.9 | -- | 1.0 | |
| 267.4 | 7,156.9 | 2,589.9 | 168.8 | 21.4 | 2.5 | 44.4 | 1.0 | |
| 45.7 | 6,955.2 | 3,458.5 | -11.6 | 2.6 | -0.6 | -- | 2.8 | |
| 120.2 | 8,011.3 | 551.4 | -189.3 | -15.6 | -26.3 | -- | 12.2 | |
| 103.0 | 6,705.9 | 1,546.2 | 279.0 | 15.0 | 23.9 | 24.6 | 5.5 | |
| 178.8 | 9,364.1 | 1,558.5 | 76.3 | 19.6 | 9.5 | 44.3 | 11.9 | |
| 328.7 | 12,946.3 | 1,454.3 | 171.1 | 11.1 | 12.1 | 76 | 8.8 | |
| 115.1 | 6,490.3 | 763.3 | 51.4 | 11.7 | 2.5 | 126.4 | 3.1 | |
| 30.5 | 13,107.2 | 6,178.4 | 626.5 | 13.0 | 11.9 | 21.5 | 2.5 |
Shareholding Pattern
View DetailsAbout Biocept (BIOC)
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the... United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware. Read more
-
Interim Pres, CEO & Chairman
Mr. Samuel D. Riccitelli
-
Interim Pres, CEO & Chairman
Mr. Samuel D. Riccitelli
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Biocept (BIOC)
What is the current share price of Biocept Inc (BIOC) Today?
The share price of Biocept Inc (BIOC) is $0.07 (NASDAQ) as of 26-Dec-2023 09:30 EDT. Biocept Inc (BIOC) has given a return of -92.09% in the last 3 years.
What is the current PB & PE ratio of Biocept Inc (BIOC)?
Since, TTM earnings of Biocept Inc (BIOC) is negative, P/E ratio is not available.
The P/B ratio of Biocept Inc (BIOC) is 0.37 times as on 26-Dec-2023, a 87 discount to its peers’ median range of 2.93 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.28
|
1.02
|
|
2021
|
-21.60
|
1.63
|
|
2020
|
-0.12
|
0.08
|
|
2019
|
0.00
|
0.00
|
|
2018
|
0.00
|
0.00
|
What is the 52 Week High and Low of Biocept Inc (BIOC)?
The 52-week high and low of Biocept Inc (BIOC) are Rs -- and Rs -- as of 24-May-2026.
What is the market cap of Biocept Inc (BIOC)?
Biocept Inc (BIOC) has a market capitalisation of $ 1 Mln as on 26-Dec-2023. As per SEBI classification, it is a company.
Should I invest in Biocept Inc (BIOC)?
Before investing in Biocept Inc (BIOC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.